Search

Search Constraints

You searched for: Author/Creator Reiser, Marcel

Search Results

1. Cost-effectiveness of rituximab in addition to fludarabine and cyclophosphamide (R-FC) for the first-line treatment of chronic lymphocytic leukemia. Issue 5 (3rd May 2016)

2. Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3, 717 patients in the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315). (February 2021)

4. FOLFIRINOX or gemcitabine/nab‐paclitaxel in advanced pancreatic adenocarcinoma: A novel validated prognostic score to facilitate treatment decision‐making in real‐world. Issue 3 (22nd September 2022)

5. Corrigendum to "Biomarker testing in non-small cell lung cancer in routine care: Analysis of the first 3, 717 patients in the German prospective, observational, nation-wide CRISP registry (AIO-TRK-0315)" [Lung Cancer 152 (2021) 174–184]. (July 2021)

6. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial. (February 2021)

7. Treatment of patients with multifocal motor neuropathy with immunoglobulins in clinical practice: the SIGNS registry. (May 2016)

8. Rituximab in combination with chemotherapy for the treatment of chronic lymphocytic leukaemia in clinical practice. (22nd March 2018)

9. Secondary antibody deficiency in chronic lymphocytic leukemia and non-Hodgkin lymphoma: Recommendations from an international expert panel. (March 2023)

10. Myelodysplastic syndromes (MDS) in regular care in Germany – the oldest patients come to the fore. Issue 5 (4th May 2018)